bioAffinity Technologies Stock Surged A Whopping 56% Today – Here’s An Important Update
Synopsis
The company reported that the use of its CyPath Lung test enabled the detection of lung cancer at an early stage.
Shares of bioAffinity Technologies (BIAF) soared 56% on Friday after the company released three additional case studies, including one in which the use of its CyPath Lung test led to the detection of lung cancer at an early, possibly curable stage.
The company also stated that two potentially risky invasive procedures were avoided for patients facing difficult healthcare choices by using the test.
CyPath Lung is a non-invasive test designed to enhance the early detection of lung cancer in patients at high risk for the disease. In clinical studies, it was demonstrated that CyPath Lung had a sensitivity of 92%, specificity of 87%, and an accuracy of 88%.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.